{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water","slug":"sentiment-at-bio-soars-as-fda-resets-dealmaking-evolves-amgen-s-tavneos-in-hot-water","published_at":"2026-07-01T08:00:00+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/sentiment-at-bio-soars-as-fda-resets-dealmaking-evolves-amgen-s-tavneos-in-hot-water","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/d71aab074556b860062ff88723341d147218d8383bcd3182383c9739bfc92046/eyJlcGlzb2RlSWQiOiJiY2IzNzE4Ni00ZmQwLTQxZWMtOTgxYy02M2Y3ZjkyNjFiMGQiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE0NDBlNWI1ZTk4OGU0ZmQ2MDEzOTI2L2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTMwX18yMC00My0zOS5tcDMifQ==.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/d71aab074556b860062ff88723341d147218d8383bcd3182383c9739bfc92046/eyJlcGlzb2RlSWQiOiJiY2IzNzE4Ni00ZmQwLTQxZWMtOTgxYy02M2Y3ZjkyNjFiMGQiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE0NDBlNWI1ZTk4OGU0ZmQ2MDEzOTI2L2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTMwX18yMC00My0zOS5tcDMifQ==.mp3","summary":"The vibe at BIO 2026 in San Diego last week was overwhelmingly positive, with attendees observing noticeable changes at the FDA and an uptick in dealmaking and IPOs. Plus, a top medical journal this week retracted a pivotal study for Amgen’s rare disease drug Tavneos, which has been in the FDA’s crosshairs since January.","meta_description":"The vibe at BIO 2026 in San Diego last week was overwhelmingly positive, with attendees observing noticeable changes at the FDA and an uptick in dealmakin…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1374,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/sentiment-at-bio-soars-as-fda-resets-dealmaking-evolves-amgen-s-tavneos-in-hot-water/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/sentiment-at-bio-soars-as-fda-resets-dealmaking-evolves-amgen-s-tavneos-in-hot-water.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}